SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs quarterly earnings report is the dominant focus, with traders watching guidance, subscriber engagement and advertising growth amid concerns about slowing growth, content quality and competition; recent leadership changes and layoffs add to the debate. Bulls see pessimism as overdone, while bears expect further weakness, leaving sentiment sharply divided ahead of the report.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Heavy buying and a sharp rebound have fueled speculation about a potential buyout or imminent company news, but neither has been confirmed. The main catalyst in discussion is the Phase 3 REGAL trials pending final analysis after the last disclosed count of 78 of 80 events; bullish traders read the CEOs optimistic anniversary post as encouraging, while skeptics point to the lack of new trial news and caution that the move may reflect trading activity.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is largely tied to anticipation of the detailed Phase 3 melanoma cancer-vaccine results with Merck at ESMO, after positive topline results sparked a major revaluation. Traders are split between momentum-driven optimism about the broader oncology platform and concerns that expectations and valuation are stretched, with some anticipating a sell-the-news pullback.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPTs sharp rebound above recent technical levels has traders discussing a possible breakout and short covering, though no specific new catalyst is confirmed. Bulls are also anticipating DM1 and FSHD siRNA readouts, while some caution that the move may reflect broader biotech strength or prove temporary.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure amid broader concerns about neocloud funding, debt, and whether AI infrastructure spending will generate adequate returns; co-CEO Daniel Roberts comments that the data centers were cash-funded and customer prepayments help cover GPU costs are being cited as reassurance. Traders are split between viewing the selloff as an oversold buying opportunity and expecting further downside, with many frustrated that IREN has lagged peers.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

ADAs weak, range-bound trading and exposure to broader crypto-market selling dominate the discussion, with many traders frustrated by failed rallies and warning of more downside. Others view the pullback as consolidation and say they are accumulating or holding, while watching technical resistance and Bitcoins direction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM shares are under pressure after a quarterly earnings beat failed to offset a narrowed full-year profit outlook that left the midpoint unchanged; weaker U.S. sales and market share also weighed on the reaction. Traders are split between viewing the selloff as overdone given stronger cash-flow guidance and a new buyback, and focusing on the lack of a higher profit outlook.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces quarterly beat and raised 2026 outlook are being overshadowed by a sharp selloff. Traders debate whether it is a sell-the-news reaction after expectations ran high or a response to rising costs, weaker cash conversion and an insurance loss, while some point to strong orders as evidence demand remains robust.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, driving attention alongside analyst upgrades. Traders are divided over the modest placebo-adjusted symptom improvement and concerns about discontinuations and agitation, with some viewing the data as a positive proof of concept and others arguing the rally may fade.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriad Genetics agreement to sell its prenatal testing business to Labcorp has driven the sharp share move, with traders viewing the cash sale as a balance-sheet and strategic reset. The community is split between bullish momentum and concern that divesting a revenue-generating unit could leave the remaining business smaller and debt pressures unresolved.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?

Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders? Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 12, 2026Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ACA, APGE, BOLD, and GBCS

SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ACA, APGE, BOLD, and GBCS SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ACA, APGE, BOLD, and GBCS PR Newswire NEW YORK, July 2, 2026 NEW YORK, July 2, 2026 /PRNewswire/ -- Class...

Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders?

Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? Are TECH, APGE, BOLD, REFI Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...

Why Did BOLD, BLZE, QNT Stocks Surge To 52-Week Highs Today 

Equity

Investors showed interest in businesses tied to artificial intelligence infrastructure, advanced biotechnology, and quantum computing.



$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD) $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD) PR Newswire NEW YORK, June 23, 2026 NEW YORK, June 23, 2026 /PRNewswire...

BOLD Stock Is Up 90% — Here's What's Behind The Biggest Rally In Company History

Boundless Bio is set to merge with Serapha Bio, with the transaction set to close in the fourth quarter of 2026.

BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Boundless Bio, Inc. (NASDAQ: BOLD) and Serapha Bio, Inc. Upon closing of the proposed transaction, Boundless Bio shareholders are expected to own approximately 3.7% of the combined company.Halper Sadeh encourages...

Market Movers Catching Transformational Catalysts

Today’s common theme is scale. Whether through regulatory advancement, access to new capital, expanding commercial opportunities, or technological innovation, companies that successfully execute during periods of rapid change often find themselves at important inflection points. $NTHI, $BOLD, $BLZE, $CRWV, $PLTR, $ZETA, $ATLN, $HSCS

Big Money Backs Base Editing, as BOLD Deal Creates Well-Funded AATD Contender

The biotechnology sector continues to reward companies developing potentially transformative genetic medicines, particularly those addressing serious diseases with limited treatment options. The latest example emerged as Boundless Bio (NASDAQ:BOLD) announced a merger agreement with privately held Serapha Bio, a clinical-stage gene editing company developing an investigational treatment for Alpha-1 Antitrypsin Deficiency (AATD), alongside a substantial $230 million private financing commitment from a syndicate of prominent healthcare investors.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

HeartSciences (NASDAQ:HSCS) stock rose 82.2% to $3.23 during Tuesday's pre-market session. The company's market cap stands at $5.6 million.
Boundless Bio (NASDAQ:BOLD) shares rose 62.85% to $2.28. Theread more...

Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in La Jolla, CA.

Boundless Bio Inc.

Neutral Sentiment

<ul class="summary-bullets"><li>Boundless Bio shares reached a 52-week high of $2.75 after the company agreed to merge with private biotech firm Serapha Bio.</li><li>Backblaze shares climbed to a two-year high of $11.85 after the company announced a $335 million, five-year storage deal with CoreWeave.</li><li>Quantinuum shares hit a record high of $81.48 after a White House executive order supported U.S. quantum technology development.&nbsp;</li></ul>Shares of Boundless Bio (BOLD), Backblaze (BLZE) and quantum computing company Quantinuum (QNT) climbed to fresh 52-week highs on Tuesday as investors poured capital into specialized technology and life sciences companies benefiting from major corporate and policy developments.While&nbsp;<a href="https://stocktwits.com/symbol/BOLD">Boundless Bio</a> and&nbsp;<a href="https://stocktwits.com/symbol/BLZE">Backblaze</a> stocks surged 85% and 43%, respectively,&nbsp;<a href="https://stocktwits.com/symbol/QNT">Quantinuum stock</a> gained over 13%.&nbsp;<h2 class="st-heading-2">BOLD Reinvents Itself Through Merger</h2>In biotechnology, Boundless Bio stock hit a 52-week high of $2.75 after agreeing to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bold-stock-surges-on-merger-news/cZKw9bzR7aD">combine</a> with privately held Serapha Bio in an all-stock transaction. The merged company plans to focus on developing clinical-stage base-editing treatments.The merged company will concentrate on advancing SERP-01, an investigational treatment designed to correct the genetic mutation most commonly responsible for severe Alpha-1 Antitrypsin Deficiency (AATD).&nbsp;The deal also includes $230 million in funding from healthcare investors, giving the company money to advance its drug development and clinical trials. Investors viewed the transaction as a major shift that positions Boundless Bio as a stronger player in the gene-editing space.On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘neutral’ territory the previous day.&nbsp;<h2 class="st-heading-2">BLZE Lands Major AI Infrastructure Opportunity</h2>Backblaze stock reached a two-year high of $11.85 after unveiling a five-year&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/blze-stock-surges-after-storage-deal-with-core-weave-retail-bulls-call-backblaze-an-emerging-ai-cloud-contender/cZKwPxSR7aQ">agreement</a> valued at approximately $335 million with AI cloud provider CoreWeave (CRWV). The arrangement positions Backblaze as a key storage provider supporting large-scale AI workloads.&nbsp;Following the update, William Blair upgraded Backblaze to Market Perform from Underperform and described the CoreWeave partnership as a transformative development.&nbsp;The firm suggested the agreement offers strong evidence that enterprise customers view Backblaze's hard-disk-drive-based storage platform as a valuable component of large-scale AI operations. According to the analyst, the announcement addresses previous concerns about the company's ability to defend its market position and execute its strategy in the AI era.Retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day.&nbsp;<h2 class="st-heading-2">Quantum Policy Boosts QNT</h2>Quantinuum also attracted significant attention after reaching a record high of $81.48, boosted by a White House executive order to ramp up U.S. quantum technology development.&nbsp;The U.S. government aims to build a quantum computer for scientific research by 2028 and expand quantum sensors and communication networks over the following years.&nbsp;Also, Federal agencies must upgrade their cybersecurity systems to use quantum-resistant encryption by 2031. This is intended to protect sensitive government data from future quantum computers that could potentially crack today's encryption methods.Retail sentiment around the stock remained in ‘bearish’ territory.&nbsp;So far this year BOLD and BLZE stocks have surged 116% and 150%, respectively. QNT stock has gained 28% since its June 4 debut.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trib-qtrx-rcon-why-these-stocks-are-surging-after-hours-today/cZKUM3NR7O7">TRIB, QTRX, RCON: Why These Stocks Are Surging After-Hours Today</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The new Crispr Therapeutics Tissue Culture Lab. 

Shares of Boundless Bio (BOLD), Backblaze (BLZE) and quantum computing company Quantinuum (QNT) climbed to fresh 52-week highs on Tuesday as investors poured capital into specialized technology and life sciences companies benefiting from major corporate a

Backblaze Inc - Ordinary Shares - Class A

CoreWeave Inc

Quantinuum Inc.

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$2.42
Prev Close	$2.31
Open	$2.33
Dividend Yield	0.00%
50-Day Moving Average	$2.73
Beta	1.19
Avg. Volume	131,689.12
PE Ratio	-0.81

52-Week High	$3.16
52-Week Low	$0.9612
Market Capitalization	$52.55M
EPS (Annual)	-$2.60
Price to Book	0.79
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

BOLD Fundamentals